\
&
Contact us
\
&
Contact us
Published on | 1 year ago
ProgrammesThe Commission is collecting feedback on the rules to set up a new scientific advisory group of independent experts on artificial intelligence.
The AI Act foresees a scientific panel of independent experts on AI to assist the AI Office and national authorities in the implementation and enforcement of the AI Act. This advisory body will play a key role in the governance, offer technical advice and input on enforcement, including the ability to alert the AI Office of risks posed by a general-purpose AI model.
The Commission will adopt an implementing act to lay down the rules and procedures for establishing and operating this scientific panel. Once these rules are in place, the Commission will launch a call for expression of interest to select the experts.
The draft implementing act is open for public feedback via the Have Your Say portal. You can Submit your comments by 15 November 2024.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
